Drug Trial Radar · NCT06209580
AMT-253 in Patients With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jan 31, 2024
Primary completion
Apr 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Multitude Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.
Conditions
- Malignant Melanoma
- Advanced Solid Tumors
Interventions
AMT-253 for injectionDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTsTime frame: 21 days after first dose
- AEsTime frame: Up to 24 months
- SAEsTime frame: Up to 24 months
- ORRTime frame: Up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.